Overview

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

Status:
Completed
Trial end date:
2018-10-30
Target enrollment:
Participant gender:
Summary
This study will determine whether in RRMS patients receiving Gilenya there is a link between disease progression and biologic markers.
Details
Lead Sponsor:
McGill University
Collaborator:
Novartis
Treatments:
Fingolimod Hydrochloride